Worldwide the prevalence of allergies is continuously rising. With one third of the global population affected by allergic conditions, it almost reaches epidemic levels. For many patients, allergies are associated with a marked reduction in physical as well as psychologic well-being and significant loss in quality of life. The steadily increasing incidence of allergies urgently calls for more targeted treatment options that need to be based on solid and reliable diagnostic assessments. With FAST-PASE®, we are developing a novel assay that meets the highest diagnostic standards.
At ATANIS Biotech, we strive to make allergy diagnosis simple and safe for both patients and physicians. Using cutting-edge technology, we have established a method to mimic allergic reactions in a test tube, keeping potentially harmful allergens away from the patient during diagnosis. All we require for the diagnostic work up is a small sample of patient derived blood serum or plasma. The final stages of development and various proof-of-concept studies are currently ongoing.
We have optimized FAST-PASE® for high throughput measurement. Using a fluorescent cellular barcoding method, we can significantly increase sample throughput. This is an ideal way to screen large patient cohorts (e.g. clinical trials) or identify lead molecules from a library of potential candidates.
From its inception in the 17th century until this day physicians and professional healthcare providers live up to the medical ethics standard of “First, do no harm" (Latin: primum non nocere). In this context, we strongly feel that the current in vivo allergy diagnosis tests including skin pricks or food challenges are in urgent need of revision and that we are in an era in which these in vivo tests could ideally be complemented by reliable and standardized in vitro assays. We are convinced that FAST-PASE® meets these criteria as it closely mimicks the patients’ in vivo situation, and - most importantly - it is putting patient safety first.